Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MRNA-1365 by Moderna for Human Metapneumovirus Infections: Likelihood of Approval
MRNA-1365 is under clinical development by Moderna and currently in Phase I for Human Metapneumovirus Infections. According to GlobalData, Phase...
MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenza A Virus, H3N2 Subtype Infections. According...
MRNA-4157 by Moderna for Renal Cell Carcinoma: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
MRNA-4157 by Moderna for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
MRNA-4157 by Moderna for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
MRNA-4157 by Moderna for Gastric Cancer: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
MRNA-1012.1 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1012.1 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1011.2 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1011.2 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1011.1 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1011.1 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1083 by Moderna for Influenzavirus B Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenzavirus B Infections. According to GlobalData, Phase...
MRNA-1083 by Moderna for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenza A Virus, H1N1 Subtype Infections. According...
MRNA-1230 by Moderna for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
MRNA-1230 is under clinical development by Moderna and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to...
MRNA-1045 by Moderna for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
MRNA-1045 is under clinical development by Moderna and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to...
MRNA-1010 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
MRNA-1010 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections. According...
MRNA-1010 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1010 is under clinical development by Moderna and currently in Phase III for Seasonal Influenza. According to GlobalData, Phase III...
MRNA-1010 by Moderna for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
MRNA-1010 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H1N1 Subtype Infections. According...
MRNA-0184 by Moderna for Congestive Heart Failure (Heart Failure): Likelihood of Approval
MRNA-0184 is under clinical development by Moderna and currently in Phase I for Congestive Heart Failure (Heart Failure). According to...
MRNA-4157 by Moderna for Metastatic Melanoma: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-3927?
MRNA-3927 is a gene therapy commercialized by Moderna, with a leading Phase II program in Propionic Acidemia. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-1647?
MRNA-1647 is a mrna vaccine commercialized by Moderna, with a leading Phase III program in Cytomegalovirus (HHV-5) Infections. According to...